Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08 2022 - 4:31PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that it will present new preclinical data on its CDK12 inhibitor
program at the American Association for Cancer Research (AACR)
Annual Meeting 2022, taking place April 8-13 in New Orleans,
Louisiana.
The online-only e-poster will include data that show Syros’
orally available, selective CDK12 inhibitor has potent single agent
activity in vitro and in vivo in multiple cancer models as well as
enhanced antitumor effect in combination with DNA damaging agents.
These data support Syros’ plans to nominate a development candidate
from its CDK12 inhibitor program in the second half of 2022.
Details of the e-poster presentation are as follows:
Presentation Title: An oral and selective CDK12 inhibitor
demonstrates robust anti-tumor activity Session Title:
Molecular Targets Session Category: Experimental and
Molecular Therapeutics Abstract Number: 5393
The abstract is now available on the AACR conference website:
https://www.aacr.org/meeting/aacr-annual-meeting-2022/. The
e-poster will become available on the AACR conference website at
1:00 p.m. ET on Friday, April 8th.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors and blood cancers. Syros also has multiple preclinical
and discovery programs in oncology and monogenic diseases. For more
information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, including without limitation statements regarding Syros’
clinical development plans, including with respect to the timing of
nomination of Syros’ next development candidate. The words
‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’
‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’
‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including Syros’ ability to: advance the development of
its programs, including CDK12, under the timelines it projects in
current and future clinical trials; demonstrate in any current and
future clinical trials the requisite safety, efficacy and
combinability of its drug candidates; sustain the response rates
and durability of response seen to date with its drug candidates;
successfully develop a companion diagnostic test to identify
patients with the RARA biomarker; obtain and maintain patent
protection for its drug candidates and the freedom to operate under
third party intellectual property; obtain and maintain necessary
regulatory approvals; identify, enter into and maintain
collaboration agreements with third parties; manage competition;
manage expenses; raise the substantial additional capital needed to
achieve its business objectives; attract and retain qualified
personnel; and successfully execute on its business strategies;
risks described under the caption “Risk Factors” in Syros’ Annual
Report on Form 10-K for the year ended December 31, 2020 and
Quarterly Report on Form 10-Q for the quarter ended September 30,
2021, each of which is on file with the Securities and Exchange
Commission; and risks described in other filings that Syros makes
with the Securities and Exchange Commission in the future. In
addition, the extent to which the COVID-19 pandemic continues to
impact Syros’ workforce and its clinical trial operations
activities, and the operations of the third parties on which Syros
relies, will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the
duration and severity of the pandemic, additional or modified
government actions, and the actions that may be required to contain
the virus or treat its impact. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Syros expressly disclaims any obligation to update any
forward-looking statements, whether because of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220308005018/en/
Media Contact: Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com
Investor Contact: Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024